en

Screening Libraries


Product Name: Format/Size Descriptions Download
Protein Degraders
(CRBN-binding)
72 compounds
For cherry-picking
Update: 2022-04
Cereblon (CRBN)-binding building blocks that are commonly used in the design of protein degradation bifunctional molecules. We favored molecules that are underrepresented among other publicly available screening collections while maintaining a balance of structural diversity and complexity.
Molecular Glues 1257 compounds
For cherry-picking
Update: 2022-04
A library of analogs of literature-reported molecular glues including phthalimide-based derivatives (e.g. lenalidomide); aryl sulfonamides (e.g. indisulam) and some others.
File# Size Descriptions Download
All Screening compounds 575302 compounds
Update: 2022-02
All screening compounds.
All Libraries File#1 (1/3)
BioDesign Library
170269 compounds
Release: 2008-2019
Update: 2021-02
File#1 contains “BioDesign” library. Our “BioDesign” approach incorporates key structural features of known pharmacologically relevant natural products (e.g. alkaloids and other secondary metabolites) into synthetically feasible medicinal chemistry scaffolds. In order to identify the privileged pharmacophores, ring systems and linkers, we have carried out statistical analysis of structural features of natural products, marketed drugs, and drug candidates. Our research shows that saturated fused ring, spiro, and bridged systems with a tendency towards multiple chiral centers are highly privileged among natural products and marketed drugs yet these structures are very poorly represented in commercial libraries. We deliberately introduced these highly privileged elements in the design of novel synthetic molecules to deliver screening compounds with a higher level of saturation (av.Fsp3>0.5), multiple chiral centers (av.≥2), and a high diversity of natural product-like frameworks.
All Libraries File#2 (2/3)
Elite Library
Synergy Library
91001 compounds
Release: 2004-2008
Update: 2021-02
File#2 contains “lead-like” compounds, also known as “Elite Library®” and "Synergy Library." These compounds have been screened against a panel of early ADMET tests (including DMSO and water solubility, PAMPA, PGP and CYP inhibition) to make sure screening hits are devoid of potential ADMET problems and are amenable for rapid hit-to-lead optimization.
All Libraries File#3 (3/3)
Gold & Platinum Collections
261120 compounds
Release: 1994-2004
Update: 2021-02
File#3 contains “historical”compounds, also known as “Gold and Platinum Collections.” It provides diverse and cost effective coverage of drug-like chemical space. The majority of compounds have a high degree of drug-likeness, in accordance with Lipinski's Rule of 5.
Pre-Plated Sets: Format/Size Descriptions Download
Signature Libraries 5556 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2020-07
ASINEX's cutting edge chemistry combined with in silico and in vitro screening validation.
Macrocycle
Pre-Plated Set
25261 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2021-09
ASINEX ‘s Macrocycle Pre-plated Sets are designed to provide the most popular screening libraries in a convenient and cost-effective manner.
Diversity
Pre-Plated Set
72578 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2022-02
Pre-Plated Set of compounds selected from ASIENX BioDesign Libraries, Elite Libraries, Synergy Libraries, Gold&Platinum Collections.
PPI Pre-Plated Set 3743 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2020-07
ASINEX has been working on the design and synthesis of protein-protein interaction (PPI) libraries since 2008. The latest generation of ASINEX PPI Library comprises molecules of various sizes, frameworks, and shapes ranging from fragment-like entities to macrocyclic derivatives designed as secondary structure mimetics or as epitope mimetics.
CNS Diversity
Pre-Plated Set
6055 compounds
Pre-Plated Set
Amount: 0.01-2.0mg
Update: 2020-07
ASINEX has selected CNS-like molecules with high diversity:
CNS-MPO > 4
CNS-MPO.v2 > 4
CNS-TEMPO < 4
Glycomimetics
Pre-Plated Set
2430 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2020-07
ASINEX has overcome these obstacles by creating a glycomimetic library that ensures the bioactive function of carbohydrates while addressing the drawbacks of carbohydrates, such as their low activity and poor drug-like properties.
Nucleoside-mimetics
Pre-Plated Set
3542 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2022-02
ASINEX has developed a number of stereo- and enantio-selective methods for the synthesis of nucleoside-like core intermediates (e. g. mimics of adenosine). These unique intermediates have been extensively decorated by various long chain amines, acids and amino acids.
Kinase Pre-Plated Set 6493 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2020-07
ASINEX facilitates the discovery of novel kinase inhibitors by providing access to our advanced collection of small molecules, fragments and macrocycles. The efficacy of our compounds has been validated through in silico modeling and in vitro on-target and phenotypic profiling. This is paralleled with 20+ years of medicinal chemistry expertise, delivering designs with outstanding ADMET and PK properties, optimizing chances in hit to candidate development.
Covalent Inhibitors
Pre-Plated Set
988 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2020-07
ASINEX has crafted a unique set of 1000 molecules containing electophylic moieties that could potentially interact with cysteine residues in the target protein. The diversity of represented scaffolds creates multiple opportunities for drug discovery in various target and therapeutic areas such as kinases, proteases, protein-protein interactions, and antimicrobials.
Phenotypic Screening Sets: Format/Size Descriptions Download
Phenotypic
Pre-Plated Set
13159 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2020-07
ASINEX has created a diverse set of molecules by applying strict physico-chemical and structural descriptors to ensure good solubility and permeability properties.
Asinex in GOSTAR 1878 compounds
41742 analogues
For cherry-picking
Update: 2020-11
Asinex have opted to use the Global Online Structure Activity Relationship Database (GOSTAR) as an integrated source of data capturing chemical, biological, pharmacological, and therapeutic parameters. The structural overlap between the Asinex (500K+) and GOSTAR (8M+) databases has revealed 17910 unique molecules with associated biological activity. Application of additional structural filters (PAINS, Eli Lilly [4-5]) has resulted in a set of 11923 compounds; diversity-oriented selection supported by computational and medicinal chemistry expertise has further refined this set resulting in 1878 molecules available for computational or in vitro evaluation. Biological diversity is represented by multiple target families where each molecule is associated with a GOSTAR record via a unique structure code identifier. For more information, please download >>>
SL#004
Oncology
Phenotypic Screening-1
(Non-Macrocycle)
80 compounds / set
Pre-Plated Set
Update: 2016
ASINEX's oncology-oriented phenotypic library includes compounds based on several scaffolds with proven cytotoxicity (sub-µM EC50 in MTT assay) against a number of cancer cell lines: MV-411 (acute monocytic leukemia), HCT-116 (human colon cancer), MCF-7 (human breast adenocarcinoma‎), A-172 (Human glioblastoma), COLO-320 (colorectal adenocarcinoma), U-937 (histiocytic lymphoma), A-375 (malignant melanoma), BXPC-3 (pancreas adenocarcinoma), U118-MG (malignant glioma), and LN-229 (glioblastoma). Some active compounds were screened in a biochemical assay showing nM level of IC50 against several kinases: Aurora A, Haspin, VEGFR, EGFR, PDGFR.
SL#023
Oncology
Phenotypic Screening-2
(Colon Cancer
Non-Macrocycle)
80 compounds / set
Pre-Plated Set
Update: 2016
ASINEX has evaluated the susceptibility of several colon cancer cell lines (HCT-116, SW-620, COLO-320, RKO) to a diverse array of small molecules and identified a series of related compounds that kill cancer cells at sub-µM concentrations with limited off target effect on healthy cells (human fibroblasts). Additional screening in a cell-based luciferase reporter assay of Wnt signaling has provided preliminary evidence of Wnt-dependent mechanism of action.
SL#035
Oncology
Phenotypic Screening-3
(Macrocycles)
80 compounds / set
Pre-Plated Set
Update: 2016
ASINEX has evaluated the susceptibility of several cancer cell lines (i.e. RKO, HCT116, Molt-4, Rs4-11, U937, A549, H1568, H23, PANC1, A2780) to an array of peptidic and non-peptidic macrocycles and identified a series of compounds that kill cancer cells at µM concentrations.
Product Name: Format/Size Descriptions Download
Asinex Building Blocks 22525 Compounds
Update: 2021-02
ASINEX’s building block encompasses the legacy of our synthetic know-how and 20+ years of medicinal chemistry expertise with an ultimate goal of delivering novel, valuable chemical monomers for increasingly challenging drug discovery programs.
In addition to commonly popular functionalities, ASINEX building blocks represent the diversity of other valuable functional groups including alkenes, epoxides, amino alcohols and polyfunctional entities, which are especially useful for template-based generation of compound libraries where a polyfunctional building block can serve as a core scaffolding structure.
ASINEX Building Blocks have been validated for both chemical stability and reactivity. Many of these building blocks have been utilized for the synthesis of our natural product-like and macrocyclic libraries as well as for advancing a number of hit-to-lead optimization projects.
Asinex Fragments 20061 Compounds
Update: 2021-02
ASINEX has two approaches for fragments.
The first approach encompasses tremendous diversity of our scaffold and synthetic handles that allows straightforward progress from fragments to leads. The subsets of fragments suitable for specific biochemical and/or biophysical screening methods are available upon request.
The second “BioDesign” approach incorporates key structural features of known pharmacologically relevant natural products (e.g. alkaloids and other secondary metabolites) into synthetically feasible medicinal chemistry scaffolds. In order to identify the privileged pharmacophores, ring systems and linkers, we have carried out statistical analysis of structural features of natural products, marketed drugs, and drug candidates. Our research shows that saturated fused ring, spiro, bridged systems and macrocycles with a tendency towards multiple chiral centers are highly privileged among natural products and marketed drugs yet these structures are very poorly represented in commercial libraries. We deliberately introduced these highly privileged elements in the design of novel fragments with a higher level of saturation, multiple chiral centers and a high diversity of natural product-like frameworks.
Asinex Building Blocks
For DNA-encoded libraries
1377 Compounds
Update: 2020-07
At Asinex we have created several hundred bi- and tri-functional low MW monomers providing flexibility in DNA tagging chemistry and allowing further opportunity for molecule growth and linking. Most of the building blocks are uniquely available from Asinex, reflecting our multi-year investment into the design and synthesis of novel nature product-like compounds.
Fragments for RNA 1065 compounds
For cherry-picking
Update: 2020-10
Product Name: Format/Size Descriptions Download
Covalent Library
(On-Demand Synthesis)
12032 compounds
On-Demand Synthesis
For Cherry Picking
Update: 2020-11
The virtual library has been created by coupling a representative set of in-stock primary and secondary amines with selected acids and aryl bromides containing a covalent warhead moiety targeting Cys. The one-step synthetic protocol allows us to synthesize the target molecule translating into a high delivery rate for a typical order selection of 10 to 100 molecules.
Product Name: Format/Size Descriptions Download
α-Helix Mimetics 6867 compounds
For cherry-picking
Update: 2020-07
It is well known that α-helix mimetics are biologically active in a number of therapeutically significant protein-protein interactions (PPIs). The file contains all available α-Helix mimetics selected from our Signature & BioDesign Libraries.
SL#030
α-Helix mimetics
80 compounds
Pre-Plated Set
Update: 2016
Using extensive computer modeling supported by in vitro experiments, ASINEX has created a number of structurally sophisticated, novel molecules based on the tetrahydropyrane scaffold that work as the effective epitope mimetics of more than 20 various helical protein interfaces (e.g. ATG3/ATG12, Bcl-2, Aquaporin 2, Protein S100-A9).
SL#032
Macrocyclic BH3 mimetics
80 compounds
Pre-Plated Set
Update: 2016
Extensive in vitro screening of the Asinex Macrocyclic collection has revealed a series of molecules showing a μM range of activity against anti-apototic proteins Bcl-2 and Mcl-1. In silico modeling studies suggest that some active macrocycles can adopt a-helix-mimetic conformations that effectively mimic the BH3-epitope of pro-apoptotic peptides (e.g. Bak, Bax).

You may also like:

Product Name: Format/Size Descriptions Download
PPI Library
(Non-Macrocyclic)
11439 compounds
For cherry-picking
Update: 2020-07
ASINEX has been working on the design and synthesis of protein-protein interaction (PPI) libraries since 2008. The file contains all available PPI (non-macrocyclic) compounds selected from our Signature & BioDesign Libraries.
PPI Library
(Macrocyclic)
3118 compounds
For cherry-picking
Update: 2020-07
The file contains all available PPI (macrocyclic) compounds selected from our Signature & BioDesign Libraries.
SL#001
Mcl-1 Apoptosis
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has developed several acylsulfonamide derivatives with Mcl-1 binding potency and improved physico-chemical characteristics.
SL#002
Bcl-xL Apoptosis
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has identified dihydrobenzofurane as a functional a-helix mimetic displaying uM Bcl-xL binding affinity determined by a fluorescence polarization assay.
SL#011
MDM2-p53
(α-Helix mimetics)
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has performed in-silico analyses of common structural futures of known MDM2 antagonists to build up a predictive pharmacophore model [1]. Several ɑ-helix mimetic scaffolds were selected as p53 backbone mimetics and p53 binding epitope mimetics [2,3]. The in vitro potency of compounds was confirmed in a fluorescence polarization assay, with the IC50s ranging from 1 to 10 µM.
SL#025
BH3 mimetics
80 compounds
Pre-Plated Set
Release: 2016
Extensive in-vitro screening of ASINEX’s natural product-like compound and α-helix mimetic collections against Bcl-2 family proteins has resulted in a series of polycyclic acids showing µM inhibitory activity of Bcl-xL. In silico simulations suggest a possible binding mode mimicking hot spot interactions of the native pro-apoptotic BAK peptide by projecting hydrophobic substituents such as Leu578, Ile581 and Ile585 of Bak.
SL#033
PD1/PD-L1 inhibitors
80 compounds
Pre-Plated Set
Release: 2016
By utilizing a combination of scaffold hopping and structure-based design strategies ASINEX has developed a library of small molecules for IDO1 drug discovery. Selected compounds have shown significant IDO1 inhibitory activity in vitro as measured in the enzymatic biochemical assays.
SL#034
Macrocyclic β-turn mimetics
80 compounds
Pre-Plated Set
Release: 2016
Asinex has created a library of partially peptidic macrocyclic beta-turn mimetics that are able to reproduce the orientation of key amino-acid side chains forming a b-turn-like motif.
SL#054
Menin-MLL inhibitors (PPI)
80 compounds
Pre-Plated Set
Release: 2016
2D similarity search through ASINEX’s compound collection has resulted in several thienopyrimidine-based analogs, close analogs of MI-503. Such analogs could be interesting chemical probes for MLL-directed research.
Product Name: Format/Size Descriptions Download
Macrocyclic Glycomimetics 1412 compounds
For cherry-picking
Update: 2020-07
Macrocyclic glycomimetics are an extremely interesting class of glycomimetics as they occupy space between small and macro molecules. Macrocyclic glycomimetics are mostly represented by naturally occurring molecules derived from marine microorganisms and bacterial or fungal metabolites.  
SL#008, 016, 036, 039, 100
Macrocyclic Glycomimetics
80 compounds x 5
Pre-Plated Set
Release: 2016-2018
Macrocyclic glycomimetics are an extremely interesting class of glycomimetics as they occupy space between small and macro molecules. Macrocyclic glycomimetics are mostly represented by naturally occurring molecules derived from marine microorganisms and bacterial or fungal metabolites.  
Product Name: Format/Size Descriptions Download
Macrocycles 10091 compounds
For cherry-picking
Update: 2021-04
ASINEX has elaborated a library of diverse macrocycles using an effective tool box of synthetic methods. The resulting scaffolds are novel and have allowed us to generate tremendously diverse, medchem-relevant, macrocyclic frameworks. Many of our macrocycles have been tested for aqueous and DMSO solubility with cut-offs applied at 10 mM in DMSO and 50 µM in PBS (pH 7.4) followed by PAMPA permeability assay.
Macrocycles for RNA 1065 compounds
For cherry-picking
Update: 2020-10
Macrocyclic Glycomimetics 1412 compounds
For cherry-picking
Update: 2020-07
Macrocyclic glycomimetics are an extremely interesting class of glycomimetics as they occupy space between small and macro molecules. Macrocyclic glycomimetics are mostly represented by naturally occurring molecules derived from marine microorganisms and bacterial or fungal metabolites.
CNS Macrocycles 1122 compounds
For cherry-picking
Update: 2020-07
SL#008, 016, 036, 039,100
Macrocyclic Glycomimetics
80 compounds x 5
Pre-Plated Set
Release: 2016-2018
Macrocyclic glycomimetics are an extremely interesting class of glycomimetics as they occupy space between small and macro molecules. Macrocyclic glycomimetics are mostly represented by naturally occurring molecules derived from marine microorganisms and bacterial or fungal metabolites.
SL#009
Cell Permeable Macrocycles
80 compounds
Pre-Plated Set
Release: 2016
This library has been tested in PAMPA assays and show permeability Pe greater than 4-16*10-6 cm/s. Generally, such compounds have excellent cellular permeability.
SL#032
Macrocyclic BH3 mimetics
80 compounds
Pre-Plated Set
Release: 2016
Extensive in vitro screening of the Asinex Macrocyclic collection has revealed a series of molecules showing a μM range of activity against anti-apototic proteins Bcl-2 and Mcl-1. In silico modeling studies suggest that some active macrocycles can adopt a-helix-mimetic conformations that effectively mimic the BH3-epitope of pro-apoptotic peptides (e.g. Bak, Bax).
SL#034
Macrocyclic β-turn mimetics
80 compounds
Pre-Plated Set
Release: 2016
Asinex has created a library of partially peptidic macrocyclic beta-turn mimetics that are able to reproduce the orientation of key amino-acid side chains forming a b-turn-like motif.
SL#035
Oncology
Phenotypic Screening-3
80 compounds
Pre-Plated Set
Release: 2016
ASINEX, has evaluated the susceptibility of several cancer cell lines (i.e. RKO, HCT116, Molt-4, Rs4-11, U937, A549, H1568, H23, PANC1, A2780) to an array of peptidic and non-peptidic macrocycles and identified a series of compounds that kill cancer cells at µM concentrations.
Product Name: Format/Size Descriptions Download
Nucleoside Mimetics 3118 compounds
For cherry-picking
Update: 2020-07
ASINEX has developed a number of stereo- and enantio-selective methods for the synthesis of nucleoside-like core intermediates (e. g. mimics of adenosine). These unique intermediates have been extensively decorated by various long chain amines, acids and amino acids.
Dinucleoside Mimetics
for RNA
696 compounds
For cherry-picking
Update: 2022-04
Systematic analysis of published small molecules with declared RNA activity has revealed several prominent structural elements that can be used as design templates for the creation of novel chemical libraries for RNA drug discovery. In particular, a combination of aromatic heterocyclic rings such as nucleobases or bioisosteric analogs with a saturated linear or ring component connected via a carbon-carbon bond are very common motifs among RNA-bound ligands with favorable drug-like properties. This observation confirms earlier published data suggesting that molecules having a favorable carbon bond saturation (defined by Fsp3) represent “biologically relevant chemical space” . In the case of RNA ligands, the right balance of aromaticity and saturation embedded in the RNA-compatible molecular framework may enhance binding probability. ASINEX have identified several such advantageous combinations.
Nucleoside-mimetics
Pre-Plated Set
3826 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2018-04
ASINEX ‘s Nucleoside-mimetics Pre-plated Sets are designed to provide popular screening libraries in a convenient and cost-effective manner.
SL#010, 052, 098
Purine-based Nucleosides
80 compounds x 3
Pre-Plated Set
Release: 2016-2018
Compounds targeting the SAM/SAH site of these enzymes offer great potential, yet very few such molecules are currently described in literature or commercially available in compound collections. To address this market need, ASINEX has used a modular approach to synthesize a library of purine-based nucleosides. The main challenge was to develop stereo- and enantio-selective methods for the synthesis of nucleotide-like cores which both mimic adenosine and are metabolically stable.
SL#099
Pyrimidine-based Nucleosides
80 compounds
Pre-Plated Set
Release: 2018
Nucleoside mimetics are the class of small molecule drugs with antitumor, antiviral, and antibacterial activity. Alterations in the base or sugar moieties can lead to significant changes in pharmacokinetic and pharmacodynamic properties of these molecules. Many convenient synthetic methods have been developed for modification of naturally occurring nucleosides, but synthetic analogs would require non-conventional approaches involving stereo- and enantio-selective reactions. In this library, a variety of pyrimidine nucleobases was linked to a number of synthetic glycomimetic cores, followed by modifications of the terminal amino group. The resulting nucleoside mimetic molecules do not have a glycosidic linkage which may be beneficial for optimizing metabolic properties.
Product Name: Format/Size Descriptions Download
Peptidomimetics 9144 compounds
For cherry-picking
Update: 2020-07
The file contains all available Peptidomimetics selected from our Signature & BioDesign Libraries.
SL#018
Spiro Peptidomimetics
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has developed several peptidomimetic scaffolds containing beta-amino acid and amino alcohol fragments integrated into a rigid spiro core. These cores have been decorated with various natural and unnatural amino acids resulting in a diverse library of tri-peptide mimetics.
SL#034
Macrocyclic β-turn mimetics
80 compounds
Pre-Plated Set
Release: 2016
Asinex has created a library of partially peptidic macrocyclic beta-turn mimetics that are able to reproduce the orientation of key amino-acid side chains forming a b-turn-like motif.
SL#040
Constrained Tetrapeptides
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has created a library of constrained tetrapeptides using a novel unnatural piperidine-containing amino acid fragment. The intrinsic rigidity from the piperidine ring is enhanced by judicial choice of other amino acids carefully decorated with diverse side chains. According to in-silico modeling some molecules can adopt a beta-turn-like conformation and can therefore be considered beta-turn mimetics.

You may also like:

Product Name: Format/Size Descriptions Download
SL#059, 060
Oxo-SpiroPyrrolidines
80 compounds x 2
Pre-Plated Set
Release: 2016
ASINEX has developed a versatile synthetic approach to skeletally diverse novel spiro scaffolds that are based on a rare combination of O- and N-containing cycles with additional synthetic handles. This allows the introduction of various peripheral fragments which, in turn, create derivatives with a very attractive physico-chemical profile.
Product Name: Format/Size Descriptions Download
Soft Electrophiles
(Covalent Library 1)
1074 compounds
For cherry-picking
Update: 2022-04
The file contains 1000+ newly synthesized compounds that passed HPLC purification and strict quality control.
Soft Electrophiles
(Covalent Library 2)
8085 compounds
For cherry-picking
Update: 2021-04
The file contains all available Soft Electrophiles selected from our Signature & BioDesign Libraries.
SL#019
Soft Electrophiles-1
(acrylamide derivatives)
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has created a library of acrylamide derivatives by combining proprietary glycomimetic or peptidomimetic fragments with selected amino acrylic acids known as “soft” electrophiles that bind to Cys residues.
SL#020
Soft Electrophiles-2
(heterocylic cinnaminc acid)
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has created a library of heterocylic cinnaminc acid derivatives by coupling with proprietary fragments. Cinnamic acid and its derivatives are found among natural products that are known for their anti-inflammatory, anti-cancer, and cardio-protective properties. [1]
SL#022
Soft Electrophiles-3
(kinase+hetero-cinnamic acids)
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has created a library of kinase-oriented small molecules by attaching electrophilic hetero-cinnamic acids to various kinase hinge-binding scaffolds. It is hypothesized that a Michael acceptor moiety of cinnamic acid is able to interact with Cys residues presented at the binding site. The resulting set represents a unique research tool for the discovery and optimization of new inhibitors across the kinome.
SL#027
Soft Electrophiles-4
(ɑ-oxyketone and
spiro-lactone)
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has created a library of ɑ-oxyketone and spiro-lactone derivatives that contain mild electrophilic functional groups. Both lactones and oxyketones provide interesting small molecule probes for covalent drug discovery across multiple disease areas [2] as they interact with nucleophilic residues (e.g. Ser, Thr, Lys and Cys) of target proteins.
SL#037
Soft Electrophiles-5
(heteroaromatic nitrile
derivatives)
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has created a library of heteroaromatic nitrile derivatives which have kinase-oriented pharmacophoric elements. These compounds are useful for the discovery of novel kinase inhibitors with improved safety, target selectivity, and pharmacokinetic properties.
Product Name: Format/Size Descriptions Download
Metal Chelate Library 1794 compounds
Release: 2021-04
The file contains ALL Metal Chelate compounds for cherry-picking.
Steroid Mimetics 1456 compounds
Release: 2020-07
The file contains ALL Steroid mimetics for cherry-picking.
Terpenoid Mimetics
4278 compounds
Release: 2020-07
ASINEX generates a unique library of skeletally diverse (saturated fused-, spiro- systems) highly oxygen rich molecules. The synthetic strategy is based on biomimetic transformations of natural terpenoid products, such as NOPOL, NEROL and GERANIOL, into novel polyether derivatives. These cyclic molecules contain several versatile functionalities (OH, NH, COOH) which are amenable to further medicinal chemistry exploration.
SL#059, 060
Oxo-SpiroPyrrolidines
80 compounds x 2
Pre-Plated Set
Release: 2016
Asinex has developed a versatile synthetic approach to skeletally diverse novel spiro scaffolds that are based on a rare combination of O- and N-containing cycles with additional synthetic handles. This allows the introduction of various peripheral fragments which, in turn, create derivatives with a very attractive physico-chemical profile.
SL#093
Gem-diMe-Heterocycles
80 compounds x 1
Pre-Plated Set
Release: 2018
The gem-dimethyl moiety is one of the most commonly occurring structural elements found in many pharmacologically relevant natural products (e.g. taxanes, statins). This element is also successfully used by medicinal chemists for improving potency and pharmacokinetic properties of drug candidates. Three-dimensional character of this element in combination with adjacent O, N heteroatoms translates into a broad diversity of molecular shapes and can facilitate the formation of a bioactive conformation upon binding to a target protein.
Enrichment of the screening library with small molecules containing this important pharmacophore can contribute to the discovery of potent hits against multiple targets.
SL#094
4-anilinopiperidines
80 compounds x 1
Pre-Plated Set
Release: 2018
4-Anilinopiperidine is a prominent pharmacophoric element recognizable among synthetic opioid analgesics. Structural variations around the 4-anilinopiperidine core greatly determine the structure–activity relationship properties such us target receptor selectivity, pharmacokinetic and safety profiles. The main structural changes may involve replacement of piperidine ring, replacement of phenyl ring and introduction of an additional substituent at the fourth position of piperidine ring.
Annulation of an additional saturated ring to the piperidine ring increases molecular rigidity leading to a series of novel octahydro‐1H‐pyrrolo[3,2‐c]pyridines. These derivatives can be potentially interesting for pharmaceutical research of novel analgesics and related applications.
SL#095
3-anilinopiperidines
80 compounds x 1
Pre-Plated Set
Release: 2018
3-Anilinopiperidine - a structural isomer of 4-anilinopiperidine which in turn represent a recognizable pharmacophore among synthetic opioid analgesics. Structural variations around the anilinopiperidine core greatly determine the structure–activity relationship properties.
Annulated bicyclic molecules, incorporating 3-anilinopiperidine fragment, can be potentially interesting for pharmaceutical research and development.
SL#096
Spiro pyrrolidines
80 compounds x 1
Pre-Plated Set
Release: 2018
3-Anilinopiperidine - a structural isomer of 4-anilinopiperidine which in turn represent a recognizable pharmacophore among synthetic opioid analgesics. Structural variations around the anilinopiperidine core greatly determine the structure–activity relationship properties. Annulated bicyclic molecules, incorporating 3-anilinopiperidine fragment, can be potentially interesting for pharmaceutical research and development.
SL#097
Medium-sized
(8 atom) Heterocycles
80 compounds x 1
Pre-Plated Set
Release: 2018
Medium-sized rings are very interesting class of molecular frameworks that can be found in many bioactive natural products and clinical candidates. Synthetic medium-sized scaffolds are underrepresented in commercial screening collections due to limited arsenal of convenient methods of their synthesis. Several efficient synthetic methods for the preparation of medium-sized rings have been reported: lactonization, lactamization, and ring-closing metathesis. However, conventional ring closing methods have their significant limitations.
Rearrangements and ring expansion reactions can introduce additional scaffold diversity and are compatible with many functional groups. A Cu-catalyzed coupling of β-lactam substrates with aryl bromides is a simple and convenient method for the preparation of 8- and 9-membered ring systems that constitute this library.
Product Name: Format/Size Descriptions Download
Antibacterial Library 5968 compounds
For cherry-picking
Update: 2020-07
ASINEX has developed a unique compound library for antibacterial research based on the proprietary natural product-like scaffolds that provide great skeletal diversity combined with the presence of polar functional groups and multiple stereogenic centers.
SL#013
Gram Negative Antibacterials
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has created a library of small molecule compounds based on an “iminosugar” scaffold. The selected molecules occupy a very specific physicochemical space of known Gram negative antibiotics. We have also screened this library against 4 selected bacterial pathogens. Several active compounds inhibited >50% of bacterial growth at a given concentration.
SL#062
Microbialb-glucuronidase inhibitors
80 compounds
Pre-Plated Set
Release: 2017
In mice models, several potent (sub-mM) inhibitors of bacterial b-glucuronidases have shown that they significantly reduce the GI damage caused by chemotherapeutic agents. Specifically, several qunoline-containing thioureas demonstrated robust selectivity toward bacterial b-glucuronidases over the human enzyme orthologs with accompanying efficacy in vivo. 80 close analogs of the reported inhibitors have been included in this library.
SL#068
Bacterial riboswitch inhibitors
80 compounds
Pre-Plated Set
Release: 2017
A group from Merck Research Laboratories published a series of structurally related compounds called “ribocils” – small molecules that target the riboflavin riboswitch. These compounds demonstrate potent antibacterial activity and inhibit riboflavin, flavin mononucleotide and flavin adenine dinucleotide synthesis - essential cofactors of bacterial metabolism. 80 close structural analogs of one of the “ribocils” have been included in this library.
Product Name: Format/Size Descriptions Download
Antiviral Library 6827 compounds
For cherry-picking
Update: 2020-07
The design and discovery of novel chemical entities with profound antiviral activity and improved safety profiles requires an access to high quality screening compounds that could deliver a meaningful starting point for further development. ASINEX has developed several libraries of small molecules and macrocycles that could facilitate the discovery of novel valuable lead compounds using either target-directed or target-unbiased screening approaches. Specific designs include a-helix mimetics, glycomimetic, diverse synthetic macrocyles, and tri/tetra-substituted scaffolds.
SL#061
Antimalarial Agents-1
80 compounds
Pre-Plated Set
Release: 2017
Several interesting novel scaffolds have been identified using this HTS platform providing promising starting points for medchem optimization. More specifically, derivatives of benzothiophene-2-carboxylic acids have been investigated to provide several important SAR insights for further development. Similarity searches in Asinex compound collection have revealed several benzothiophene-2-carboxamide core-containing molecules that could be used for additional exploration of this promising chemoptype.
SL#069
Interferon inducers
80 compounds
Pre-Plated Set
Release: 2017
The first small molecule interferon (INF) inducers were discovered several decades ago as a result of an extensive search of antiviral agents. The mode of action of many INF inducers remains unknown, while many researchers connect interferon induction with the function of the ER-resident protein STING. Small molecules 10-carboxymethyl-9-acridanone (CMA), (5,6-dimethyl-9-oxo-9H-xanthen-4-yl)-acetic acid (DMXAA), and G10 were shown to trigger INF induction in a STING-dependent manner. 80 close structural analogs of CMA, DMXAA, and G10 have been included in this library.
SL#070
HIV TAR RNA small molecule binders
80 compounds
Pre-Plated Set
Release: 2017
Using a combination of biophysical and cell-based experiments a group from the National Cancer Institute has identified several derivatives of thienopyridine and phenothiazine that bind to HIV transactivation response (TAR) with high potency and selectivity. Close analogs of the reported hits might be interesting for further SAR exploration and elucidation of specific RNA-binding elements.

You may also like:

Product Name: Format/Size Descriptions Download
α-Helix Mimetics 6867 compounds
For cherry-picking
Update: 2020-07
It is well known that α-helix mimetics are biologically active in a number of therapeutically significant protein-protein interactions (PPIs). The file contains all available α-Helix mimetics selected from our Signature & BioDesign Libraries.
SL#030
α-Helix mimetics
80 compounds
Pre-Plated Set
Update: 2016
Using extensive computer modeling supported by in vitro experiments, ASINEX has created a number of structurally sophisticated, novel molecules based on the tetrahydropyrane scaffold that work as effective epitope mimetics of more than 20 various helical protein interfaces (e.g. ATG3/ATG12, Bcl-2, Aquaporin 2, Protein S100-A9).
SL#032
Macrocyclic BH3 mimetics
80 compounds
Pre-Plated Set
Update: 2016
Extensive in vitro screening of the Asinex Macrocyclic collection has revealed a series of molecules showing a μM range of activity against anti-apototic proteins Bcl-2 and Mcl-1. In silico modeling studies suggest that some active macrocycles can adopt a-helix-mimetic conformations that effectively mimic the BH3-epitope of pro-apoptotic peptides (e.g. Bak, Bax).
Product Name: Format/Size Descriptions Download
Nucleoside Mimetics 3118 compounds
For cherry-picking
Update: 2020-07
ASINEX has developed a number of stereo- and enantio-selective methods for the synthesis of nucleoside-like core intermediates (e. g. mimics of adenosine). These unique intermediates have been extensively decorated by various long chain amines, acids and amino acids.
Dinucleoside Mimetics
for RNA
842 compounds
For cherry-picking
Update: 2020-10
Systematic analysis of published small molecules with declared RNA activity has revealed several prominent structural elements that can be used as design templates for the creation of novel chemical libraries for RNA drug discovery. In particular, a combination of aromatic heterocyclic rings such as nucleobases or bioisosteric analogs with a saturated linear or ring component connected via a carbon-carbon bond are very common motifs among RNA-bound ligands with favorable drug-like properties. This observation confirms earlier published data suggesting that molecules having a favorable carbon bond saturation (defined by Fsp3) represent “biologically relevant chemical space” . In the case of RNA ligands, the right balance of aromaticity and saturation embedded in the RNA-compatible molecular framework may enhance binding probability. ASINEX have identified several such advantageous combinations.
Nucleoside-mimetics
Pre-Plated Set
3826 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2018-04
ASINEX ‘s Nucleoside-mimetics Pre-plated Sets are designed to provide popular screening libraries in a convenient and cost-effective manner.
SL#010, 052, 098
Purine-based Nucleosides
80 compounds x 3
Pre-Plated Set
Release: 2016-2018
Compounds targeting the SAM/SAH site of these enzymes offer great potential, yet very few such molecules are currently described in literature or commercially available in compound collections. To address this market need, ASINEX has used a modular approach to synthesize a library of purine-based nucleosides. The main challenge was to develop stereo- and enantio-selective methods for the synthesis of nucleotide-like cores which both mimic adenosine and are metabolically stable
SL#099
Pyrimidine-based Nucleosides
80 compounds
Pre-Plated Set
Release: 2018
Nucleoside mimetics are the class of small molecule drugs with antitumor, antiviral, and antibacterial activity. Alterations in the base or sugar moieties can lead to significant changes in pharmacokinetic and pharmacodynamic properties of these molecules. Many convenient synthetic methods have been developed for modification of naturally occurring nucleosides, but synthetic analogs would require non-conventional approaches involving stereo- and enantio-selective reactions. In this library, a variety of pyrimidine nucleobases was linked to a number of synthetic glycomimetic cores, followed by modifications of the terminal amino group. The resulting nucleoside mimetic molecules do not have a glycosidic linkage which may be beneficial for optimizing metabolic properties.
Product Name: Format/Size Descriptions Download
Glycomimetics 4292 compounds
For cherry-picking
Update: 2020-07
The file contains all available Glycomimetics selected from our Signature & BioDesign Libraries.
Macrocyclic Glycomimetics 1412 compounds
For cherry-picking
Update: 2020-07
Macrocyclic glycomimetics are an extremely interesting class of glycomimetics as they occupy space between small and macro molecules. Macrocyclic glycomimetics are mostly represented by naturally occurring molecules derived from marine microorganisms and bacterial or fungal metabolites.
SL#006, 007, 017, 028
Glycomimetics
80 compounds x 4
Pre-Plated Set
Release: 2016
ASINEX has overcome these obstacles by creating a glycomimetic library that ensures the bioactive function of carbohydrates while addressing the drawbacks of carbohydrates, such as their low activity and poor drug-like properties.
SL#038
Glycomimetics/Immunology
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has employed unique synthetic methods to create a library of synthetic glycomimetics where the carbohydrate ring is replaced by pyrrolidine.
SL#008, 016, 036, 039, 100
Macrocyclic Glycomimetics
80 compounds x 5
Pre-Plated Set
Release: 2016-2018
Macrocyclic glycomimetics are an extremely interesting class of glycomimetics as they occupy space between small and macro molecules. Macrocyclic glycomimetics are mostly represented by naturally occurring molecules derived from marine microorganisms and bacterial or fungal metabolites
SL#055, 056
Arabinose Glycomimetics
80 compounds x 2
Pre-Plated Set
Release: 2016
ASINEX has created a library of glycomimetic derivatives based on D-(-)-Arabinose. The presence of amine in the resulting scaffold allows a broad variation of substituents while retaining the stereochemical configuration of the cyclic amino polyol scaffold.
SL#057, 058
Carbocyclic Glycomimetics
80 compounds x 2
Pre-Plated Set
Release: 2016
ASINEX has developed an efficient synthetic strategy to create five and six-membered carbocylic glycomimetic scaffolds with strategically orientated peripheral substituents.
Product Name: Format/Size Descriptions Download
CNS Library 120883 compounds
For cherry-picking
Update: 2020-07
The file contains all available CNS biased compounds selected from our Signature & BioDesign Libraries.
CNS Macrocycles 1122 compounds
For cherry-picking
Update: 2020-07
CNS Diversity
Pre-Plated Set
6055 compounds
Pre-Plated Set
Amount: 0.01-2.0mg
Release: 2020-07
ASINEX has selected CNS-like molecules with high diversity:
CNS-MPO > 4
CNS-MPO.v2 > 4
CNS-TEMPO < 4
SL#044
CNS set (PAMPA BBB)
80 compounds
Pre-Plated Set
Release: 2016
In-vitro screening of ASINEX’s BioDesign collection has revealed a number of CNS-like molecules with high PAMPA-BBB permeability properties (Pe >10 x 10-6cm/s). A diversity-selection of the most permeable compounds has been used as the basis for this library which can be further expanded through available analogs.
SL#048
ApoE activators (agonist)
80 compounds
Pre-Plated Set
Release: 2016
A library of 15000 natural product like compounds has been screened in vitro in CCF-STTG (human astrocytoma) cells against ApoE secretion using an ELISA assay. A number of primary hits have been further optimized to provide compounds with ApoE secretion agonistic activity in the range of 0.6-15 µM.
SL#073
CNS kinase -
DLK (MAP3K12)
80 compounds
Pre-Plated Set
Release: 2017
80 analogs of the reported hits have been included in this library.
SL#076
OxyTerpenoids for CNS
80 compounds
Pre-Plated Set
Release: 2017
ASINEX has developed a synthetic toolbox which has enabled us to generate a unique library of skeletally diverse terpenoid-like molecules.
These molecules are particularly interesting for CNS-related research due to favorable CNS-likeness properties: CNS-MPO score >4 and high PAMPA-BBB.
SL#077
Morpholines for CNS
80 compounds
Pre-Plated Set
Release: 2017
Asinex has developed several novel lead-like morpholine-containing small molecules, that predictably demonstrate favorable CNS-like properties (CNSMPO >4).
SL#078
Sympathomimetics
chemical probes
80 compounds
Pre-Plated Set
Release: 2017
Asinex has developed several analogs of Propranolol - first clinically successful sympathomimetic, containing the characteristic 3-amino-2-hydroxypropanol fragment.
SL#079
Piperidines for CNS-1
80 compounds
Pre-Plated Set
Release: 2017
Asinex have created a series of novel piperidine containing molecules, that have favorable CNS-like physico-chemical properties making these compounds an interesting screening set for CNS-directed research.
SL#080
Analgesic for CNS
80 compounds
Pre-Plated Set
Release: 2017
Asinex has created several novel 3-substituted 2-benzylpiperidine derivatives that represent an interesting chemotype for studying opiod receptor signaling.
SL#091
Fatty Acid Amide Hydrolase
(FAAH) inhibitors
80 compounds
Pre-Plated Set
Release: 2018
Synthetic inhibitors of FAAH have been explored as promising candidates for the treatment of several disease conditions including pain, inflammation and mood disorders. Several promising chemical series such as carbamates and arylureas, have been optimized and moved into clinical trials. Analogs of the reported clinical candidates were included into this library.
Product Name: Format/Size Descriptions Download
Epigenetic Library 5391 compounds
For cherry-picking
Update: 2020-07
The file contains all available Epigenetic compounds selected from our Signature & BioDesign Libraries.
SL#031
EZH2 inhibitors
80 compounds
Pre-Plated Set
Release: 2016
Using a combination of structure and ligand based design, ASINEX has created a library of aminomethyl quinolone-2 derivatives decorated by ortho-substituted heteroaromatic acids. The resulting amides share some similarity with published EZH2 inhibitors and may provide useful molecular probes for understanding EZH2 functional activity and developing novel, potent anti-cancer agents.
SL#042
Protein-lysine-
methyltransferase
80 compounds
Pre-Plated Set
Release: 2016
The Protein Data Bank has more than 1300 different PKMT entries in their apo- or small molecule-bound forms which provides a significant amount of information for de novo design of novel selective inhibitors. Additionally, new compounds with validated in vitro inhibitory activity toward PKMTs represent an attractive starting point for the rational creation of more effective inhibitors. In this library we highlight several compounds that demonstrate a μM range of activity against SETD8 – an emerging target for anti-cancer intervention.
SL#045
HDAC inhibitors
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has screened a library of 50000 small molecules and identified a number of hits with significant HDAC (HeLa cell lysate) inhibitory activity.
SL#047
BET inhibitors
80 compounds
Pre-Plated Set
Release: 2016
By utilizing a combination of ligand-based and structure-based design methods, ASINEX has created a library of novel compounds that were shown to inhibit BRD2 and BRD4 proteins in vitro.
SL#086
Histone demethylases
(KDMs) inhibitors
80 compounds
Pre-Plated Set
Release: 2018
A series of thieno[3,2-b]pyrrole-5-carboxamides derivatives have been identified as µM inhibitors of KDM1A using an HTS workflow and supported by subsequent structure-based design studies.
A similarity search through ASINEX’s compound collection identified several close analogs of the reported inhibitors that could be interesting for KDM-related research and drug discovery.

You may also like:

Product Name: Format/Size Descriptions Download
Nucleoside Mimetics 3118 compounds
For cherry-picking
Update: 2020-07
ASINEX has developed a number of stereo- and enantio-selective methods for the synthesis of nucleoside-like core intermediates (e. g. mimics of adenosine). These unique intermediates have been extensively decorated by various long chain amines, acids and amino acids.
Dinucleoside Mimetics
for RNA
842 compounds
For cherry-picking
Update: 2020-10
Systematic analysis of published small molecules with declared RNA activity has revealed several prominent structural elements that can be used as design templates for the creation of novel chemical libraries for RNA drug discovery. In particular, a combination of aromatic heterocyclic rings such as nucleobases or bioisosteric analogs with a saturated linear or ring component connected via a carbon-carbon bond are very common motifs among RNA-bound ligands with favorable drug-like properties. This observation confirms earlier published data suggesting that molecules having a favorable carbon bond saturation (defined by Fsp3) represent “biologically relevant chemical space” . In the case of RNA ligands, the right balance of aromaticity and saturation embedded in the RNA-compatible molecular framework may enhance binding probability. ASINEX have identified several such advantageous combinations.
Nucleoside-mimetics
Pre-Plated Set
3826 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2018-04
ASINEX ‘s Nucleoside-mimetics Pre-plated Sets are designed to provide popular screening libraries in a convenient and cost-effective manner.
SL#010, 052, 098
Purine-based Nucleosides
80 compounds x 3
Pre-Plated Set
Release: 2016-2018
Compounds targeting the SAM/SAH site of these enzymes offer great potential, yet very few such molecules are currently described in literature or commercially available in compound collections. To address this market need, ASINEX has used a modular approach to synthesize a library of purine-based nucleosides. The main challenge was to develop stereo- and enantio-selective methods for the synthesis of nucleotide-like cores which both mimic adenosine and are metabolically stable.
SL#099
Pyrimidine-based
Nucleosides
80 compounds
Pre-Plated Set
Release: 2018
Nucleoside mimetics are the class of small molecule drugs with antitumor, antiviral, and antibacterial activity. Alterations in the base or sugar moieties can lead to significant changes in pharmacokinetic and pharmacodynamic properties of these molecules. Many convenient synthetic methods have been developed for modification of naturally occurring nucleosides, but synthetic analogs would require non-conventional approaches involving stereo- and enantio-selective reactions. In this library, a variety of pyrimidine nucleobases was linked to a number of synthetic glycomimetic cores, followed by modifications of the terminal amino group. The resulting nucleoside mimetic molecules do not have a glycosidic linkage which may be beneficial for optimizing metabolic properties.
Product Name: Format/Size Descriptions Download
GPCR Library 8532 compounds
For cherry-picking
Update: 2020-07
The file contains all available GPCR compounds selected from our Signature & BioDesign Libraries.
Lipid GPCR Library 2344 compounds
Update: 2020-07
The file contains ALL Lipid GPCR compounds for cherry-picking.
Peptide GPCR Library
(Macrocycles)
6285 compounds
Release: 2020-07
The file contains ALL Peptidergic GPCR macrocycles for cherry-picking.
SL#014
Peptide GPCRs,
SST4R agonists
80 compounds
Pre-Plated Set
Release: 2016
ASINEX's GPCR screening platform including an SST4 binding assay, SST4 GTPγS assay, and SST4 cell functional assays, has identified several potent modulators of SST4R.
SL#078
Sympathomimetics
chemical probes
80 compounds
Pre-Plated Set
Release: 2017
Asinex has developed several analogs of Propranolol - first clinically successful sympathomimetic, containing the characteristic 3-amino-2-hydroxypropanol fragment.
SL#088
Free Fatty Acid Receptor
(FFAR) Regulators
80 compounds
Pre-Plated Set
Release: 2018
Known small molecule agonists of FFA receptors share some common pharmacophoric features, such as a carboxylic acid moiety attached directly or via an aliphatic tail to an aromatic core. A pharmacophore search through ASINEX’s compound collection identified several hits that can be explored for FFA research and drug discovery.
SL#089
Dopamine receptor type 2
(DRD2) inhibitors
80 compounds
Pre-Plated Set
Release: 2018
Several recent studies demonstrated that dopamine receptors D2 are associated with tumorigenesis. Some antipsychotic drugs showed anti neoplastic effects on human cancers as adjuvants enhancing the effi¬cacy of anticancer therapy in breast and colon cancer cell lines. A pharmacophore search through ASINEX’s compound collection identified several molecules that can be explored for GPCR research and anticancer drug discovery.
SL#090
κ-Opioid receptor
(KOR) agonists
80 compounds
Pre-Plated Set
Release: 2018
Recent report shows a novel chemical series of KOR agonists based on a triazole scaffold. The lead compound Triazole 1.1 was tested in vivo and demonstrated a preservation of the analgesic properties with no signs of the sedating or dysphoric effects of typical KOR agonists.
Analogs of the reported triazole lead series were included into this library.
Product Name: Format/Size Descriptions Download
Ion-Channel Library 8559 compounds
For cherry-picking
Update: 2020-07
The file contains all available Ion-Channel compounds selected from our Signature & BioDesign Libraries. For more information, please download >>>
SL#005, 051
Ion Channel Modulators
Nav1.8
80 compounds x 2
Pre-Plated Set
Release: 2016
Based on the analysis of several known NaV1.8-blockers ASINEX has developed a pharmacophore model which has been used to carry out an exhaustive search on a 20000+ set of natural product-like compounds. The highest scoring compounds were screened in vitro in the human Nav1.8/β3 sodium channel cell line.
SL#092
Ion Channel
Modulators Nav1.7
80 compounds
Pre-Plated Set
Release: 2018
A recent study reported a series of pyrrolopyrimidine derivatives as highly potent and state-dependent inhibitors of Nav1.7. Analogs of the reported chemotypes were included into this library.
SL#041
Voltage-gated
sodium channels
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has identified a number of ion-channel modulators against undisclosed voltage-gated ion channels. This library is useful for ion channel research and drug discovery.
SL#064
TMEM16A
Channel Modulators
80 compounds
Pre-Plated Set
Release: 2017
Transmembrane protein 16A (TMEM16A) inhibitors have been proposed for treatment of disorders of epithelial fluid and mucus secretion, hypertension, asthma, and possibly cancer. A recent study revealed that a series of 2-acylaminocycloalkylthiophene-3-carboxylic acid arylamides can inhibit TMEM16A at low nM concentrations. 80 close analogs of the most potent inhibitor 10bm were included into this library.
SL#081
Aankyrin-like receptor family
(TRPA1) Agonists
80 compounds
Pre-Plated Set
Release: 2018
A recent study reported several electrophilic compounds that covalently modify reactive cysteine residues revealing important insights about the key SH groups involved in TRPA1 activation. Analogs of the reported molecules were included into this library.
SL#084
Inhibitors of TRPC3/6/7
80 compounds
Pre-Plated Set
Release: 2018
A series of pyrazolopyrimidine derivatives has been recently discovered as potent agonists of TRPC3/6/7 channels. Structural analogs of the reported ion channel modulators were included into this library.
Product Name: Format/Size Descriptions Download
Kinase Library 6084 compounds
For cherry-picking
Update: 2020-07
ASINEX facilitates the discovery of novel kinase inhibitors by providing access to our advanced collection of small molecules, fragments and macrocycles. The efficacy of our compounds has been validated through in silico modeling and in vitro on-target and phenotypic profiling. This is paralleled with 20+ years of medicinal chemistry expertise, delivering designs with outstanding ADMET and PK properties, optimizing chances in hit to candidate development. F
Kinase Type II Inhibitors 2376 compounds
For cherry-picking
Update: 2020-07
ASINEX has designed molecules that could act as Type-II Kinase ligands using a proprietary computational algorithm.
SL#015
Ser-Thr Kinases
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has designed molecules that in vitro target a number of Ser-Thr Kinases including Aurora A, Aurora B, Haspin, and B-Raf.
SL#026
IRAK4 inhibitors
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has created a series of IRAK4-oriented compounds by combining the IRAK4 hinge binding motif with proprietary natural product-like fragments. Several compounds from this library were screened against IRAK4 kinase in vitro and showed sub-uM IC50. Sunitinib was also included in the library as a reference compound.
SL#046
EGFR, PDGFR alpha & beta inhibitors
80 compounds
Pre-Plated Set
Release: 2016
Screening of the ASINEX BioDesign Libraries has revealed a number of potent (IC50 < 1µM) inhibitors of EGFR and PDGFRɑ/β . This library is a useful starting point for kinase-oriented research and drug discovery.
SL#073
CNS Kinase - DLK (MAP3K12)
80 compounds
Pre-Plated Set
Release: 2017
80 analogs of the reported hits have been included in this library.
SL#074
PKCε translocation inhibitors
80 compounds
Pre-Plated Set
Release: 2017
ATP-competitive inhibitors of the PKC family show a lack of desired selectivity. In order to identify a selective inhibitor of PKCε signaling, research pointed to a molecule that can disrupt the PKCε/RACK2 interaction.
A series of thienoquinolines was shown to prevent the PKCε/RACK2 interaction at low uM concentrations. Initial hits originated from the Asinex collections; analogs of the reported hits were included in this library.
SL#082
p38 Inhibitors for
anti-Inflammatory Drug Discovery
80 compounds
Pre-Plated Set
Release: 2018
A number of natural product and synthetic inhibitors of p38 kinase family has been reported showing a promising anti-inflammatory activity in several models. However, low specificity, low efficacy, and high toxicity of known candidates, creates an unmet need for novel agents.
Using a proprietary library design platform ASINEX has created molecules that in vitro target p38a in a range of therapeutically relevant concentrations.
Product Name: Format/Size Descriptions Download
PPI Library
(Non-Macrocyclic)
11439 compounds
For cherry-picking
Update: 2020-07
ASINEX has been working on the design and synthesis of protein-protein interaction (PPI) libraries since 2008. The file contains all available PPI (non-macrocyclic) compounds selected from our Signature & BioDesign Libraries.
PPI Library
(Macrocyclic)
3118 compounds
For cherry-picking
Update: 2020-07
The file contains all available PPI (macrocyclic) compounds selected from our Signature & BioDesign Libraries.
SL#001
Mcl-1 Apoptosis
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has developed several acylsulfonamide derivatives with Mcl-1 binding potency and improved physico-chemical characteristics.
SL#002
Bcl-xL Apoptosis
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has identified dihydrobenzofurane as a functional a-helix mimetic displaying uM Bcl-xL binding affinity determined by a fluorescence polarization assay.
SL#011
MDM2-p53 (α-Helix mimetics)
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has performed in-silico analyses of common structural futures of known MDM2 antagonists to build up a predictive pharmacophore model [1]. Several ɑ-helix mimetic scaffolds were selected as p53 backbone mimetics and p53 binding epitope mimetics [2,3]. The in vitro potency of compounds was confirmed in a fluorescence polarization assay, with the IC50s ranging from 1 to 10 µM.
SL#025
BH3 mimetics
80 compounds
Pre-Plated Set
Release: 2016
Extensive in-vitro screening of ASINEX’s natural product-like compound and α-helix mimetic collections against Bcl-2 family proteins has resulted in a series of polycyclic acids showing µM inhibitory activity of Bcl-xL. In silico simulations suggest a possible binding mode mimicking hot spot interactions of the native pro-apoptotic BAK peptide by projecting hydrophobic substituents such as Leu578, Ile581 and Ile585 of Bak.
SL#032
Macrocyclic BH3 mimetics
80 compounds
Pre-Plated Set
Release: 2016
Extensive in vitro screening of the Asinex Macrocyclic collection has revealed a series of molecules showing a μM range of activity against anti-apototic proteins Bcl-2 and Mcl-1. In silico modeling studies suggest that some active macrocycles can adopt a-helix-mimetic conformations that effectively mimic the BH3-epitope of pro-apoptotic peptides (e.g. Bak, Bax).
SL#033
PD1/PD-L1 inhibitors
80 compounds
Pre-Plated Set
Release: 2016
By utilizing a combination of scaffold hopping and structure-based design strategies ASINEX has developed a library of small molecules for IDO1 drug discovery. Selected compounds have shown significant IDO1 inhibitory activity in vitro as measured in the enzymatic biochemical assays.
SL#034
Macrocyclic β-turn mimetics
80 compounds
Pre-Plated Set
Release: 2016
Asinex has created a library of partially peptidic macrocyclic beta-turn mimetics that are able to reproduce the orientation of key amino-acid side chains forming a b-turn-like motif.
SL#054
Menin-MLL inhibitors (PPI)
80 compounds
Pre-Plated Set
Release: 2016
2D similarity search through ASINEX’s compound collection has resulted in several thienopyrimidine-based analogs, close analogs of MI-503. Such analogs could be interesting chemical probes for MLL-directed research.

References:

  1. J Med Chem. 2015 Feb 12;58(3):1038-52. doi: 10.1021/jm501092z
  2. Med. Chem. Commun., 2013, 4, 1597-1603 doi: 10.1039/C3MD00211J
  3. Chem Biol Drug Des. 2014 Nov;84(5):585-92. doi: 10.1111/cbdd.12351

You may also like:

Product Name: Format/Size Descriptions Download
α-Helix Mimetics 6867 compounds
For cherry-picking
Update: 2020-07
It is well known that α-helix mimetics are biologically active in a number of therapeutically significant protein-protein interactions (PPIs). The file contains all available α-Helix mimetics selected from our Signature & BioDesign Libraries.
SL#030
α-Helix mimetics
80 compounds
Pre-Plated Set
Update: 2016
Using extensive computer modeling supported by in vitro experiments, ASINEX has created a number of structurally sophisticated, novel molecules based on the tetrahydropyrane scaffold that work as effective epitope mimetics of more than 20 various helical protein interfaces (e.g. ATG3/ATG12, Bcl-2, Aquaporin 2, Protein S100-A9).
SL#032
Macrocyclic BH3 mimetics
80 compounds
Pre-Plated Set
Update: 2016
Extensive in vitro screening of the Asinex Macrocyclic collection has revealed a series of molecules showing a μM range of activity against anti-apototic proteins Bcl-2 and Mcl-1. In silico modeling studies suggest that some active macrocycles can adopt a-helix-mimetic conformations that effectively mimic the BH3-epitope of pro-apoptotic peptides (e.g. Bak, Bax).
Product Name: Format/Size Descriptions Download
Dinucleoside Mimetics for RNA 696 compounds
For cherry-picking
Update: 2022-04
Systematic analysis of published small molecules with declared RNA activity has revealed several prominent structural elements that can be used as design templates for the creation of novel chemical libraries for RNA drug discovery. In particular, a combination of aromatic heterocyclic rings such as nucleobases or bioisosteric analogs with a saturated linear or ring component connected via a carbon-carbon bond are very common motifs among RNA-bound ligands with favorable drug-like properties. This observation confirms earlier published data suggesting that molecules having a favorable carbon bond saturation (defined by Fsp3) represent “biologically relevant chemical space” . In the case of RNA ligands, the right balance of aromaticity and saturation embedded in the RNA-compatible molecular framework may enhance binding probability. ASINEX have identified several such advantageous combinations.
Macrocycles for RNA 1790 compounds
For cherry-picking
Update: 2020-10
Fragments for RNA 1065 compounds
For cherry-picking
Update: 2020-10
RNA-targeting Small Molecules

(RNA targeted library)
(RNA compound library)
1862 compounds
For cherry-picking
Update: 2019-04
Modulation of the functional roles of RNAs in prokaryotic and eukaryotic cells with small molecules is becoming increasingly important in drug discovery. Unfortunately, to this point, there has been little clinical success involving RNA-binding small molecules. We, therefore, believe that a critical component for future RNA-directed drug discovery is access to the appropriate screening collection containing small molecules with an increased probability of engaging the target in an advantageous way. The choice of such a library could be based on structural knowledge of the binding cavity, the physicochemical properties complementary to RNA, along with other pharmacological properties such as cellular permeability.

In order to understand the scope of potentially druggable RNA targets and applicable screening libraries we analyzed RNA structures in the PDB database extracting 30 of the most promising macromolecule-ligand complexes. Based on these 30 RNA structures, we have created 16 pharmacophore queries that capture the characteristic features of a small molecule ligand bound to RNA. We then applied the resulting queries in searching through ASINEX BioDesign and Elite collections. These searches resulted in several hundred molecules that could be tagged with a particular pharmacophore.
SL#063
Preferred RNA-binding motifs
2-phenyl benzimidazole
80 compounds
Pre-Plated Set
Release: 2017
A small molecule Targapremir-210 belonging to the 2-phenyl benzimidazole scaffold was shown to bind to the Dicer site of the miR-210 hairpin precursor inhibiting production of the mature miRNA. miR-210 regulates hypoxia inducible factors and plays a critical role in cancer maintenance. Small molecules that can selectively target specific miRNAs are promising therapeutic agents against several cancers.
SL#066
Inhibitors of miсroRNA-21
80 compounds
Pre-Plated Set
Release: 2017
Small molecules that can bind directly to miR-21 have been suggested as a promising new therapy for the treatment of cancer. Screening a large library of druglike small molecules has identified several chemotypes that bind to the pre-miR-21 hairpin with high selectivity against other oligonucleotides. The most potent hit molecules share the common 1-amino-3-(9H-carbazol-9-yl)propan-2-ol scaffold which can be considered a privileged fragment.
SL#067
Inhibitors of miсroRNA-29
80 compounds
Pre-Plated Set
Release: 2017
It has been hypothesized that compounds having at least one basic nitrogen are favored due to possible electrostatic interaction with negatively charged RNAs. In a paper submitted by the Prof. Nakatani group, several small molecules were disclosed exhibiting detectable affinity to pre-miR-29a - a miRNA involved in multiple pathophysiological processes. Analogs of one of the hit molecules (S-6) have been included in this library.
Product Name: Format/Size Descriptions Download
Signal Pathway Inhibitor Library 4817 compounds
For cherry-picking
Update: 2020-07
The file contains all available Signal Pathway Inhibitors selected from our Signature & BioDesign Libraries.
SL#003
Wnt/β-catenin Pathway Inhibitors
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has screened 21000 small molecules in a luciferase reporter assay using the colorectal cancer cell lines, SW620 (APC mutation) and HCT116 (GSK3b mutation). Selected primary hits were optimized to yield an array of active compounds showing EC50 0.1-5 uM. The most promising compounds down regulate the expression of the key WNT oncogenes: DKK, cycD, CD44.
SL#012
Wnt/β-catenin Pathway Activators
80 compounds
Pre-Plated Set
Release: 2016
ASINEX, has screened a proprietary collection of 20000+ natural product like molecules, nucleoside mimetics, and glycomimetics in a luciferase reporter assay designed to monitor activation of the Wnt / β-catenin signaling pathway in C2C12 model cells. Primary hits were further optimized to generate a library of potent small molecule Wnt pathway activators with an EC50 range of 0.5-30 µM.
SL#024
STAT3 inhibitors
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has screened 10000+ natural product-like compounds in HepG2 cells transfected with the STAT3 reporter. As a result, several hit clusters were identified with sub uM potency in a cell-based assay. Structurally, the hit compounds incorporate several interesting natural product-like features such us bicyclic spiro-cores, iminosugars, and saturated fused rings. These compounds can be used as probes for further chemical biology studies across the STAT3 pathway.
SL#048
ApoE activators (agonist)
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has screened a library of 15000 natural product like compounds in CCF-STTG (human astrocytoma) cells against ApoE secretion. A number of primary hits have been further optimized to provide compounds with ApoE secretion agonistic activity in the range of 0.6-15 µM.
SL#049
SMO inhibitors
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has designed a library of small molecules sharing high structural similarity with approved drugs making them an interesting starting point for SMO-oriented drug discovery and research.
SL#075
WNT pathway inhibitors (PORCN)
80 compounds
Pre-Plated Set
Release: 2017
Analogs of GNF-1331 have been included in this library.

You may also like:

Phenotypic Screening Sets: Format/Size Descriptions Download
Phenotypic Pre-Plated Set 13159 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2020-07
ASINEX has created a diverse set of molecules by applying strict physico-chemical and structural descriptors to ensure good solubility and permeability properties.
Asinex in GOSTAR 1878 compounds
41742 analogues
For cherry-picking
Update: 2020-11
Asinex have opted to use the Global Online Structure Activity Relationship Database (GOSTAR) as an integrated source of data capturing chemical, biological, pharmacological, and therapeutic parameters. The structural overlap between the Asinex (500K+) and GOSTAR (8M+) databases has revealed 17910 unique molecules with associated biological activity. Application of additional structural filters (PAINS, Eli Lilly [4-5]) has resulted in a set of 11923 compounds; diversity-oriented selection supported by computational and medicinal chemistry expertise has further refined this set resulting in 1878 molecules available for computational or in vitro evaluation. Biological diversity is represented by multiple target families where each molecule is associated with a GOSTAR record via a unique structure code identifier.
SL#004
Oncology Phenotypic Screening-1
(Non-Macrocycle)
80 compounds / set
Pre-Plated Set
Update: 2016
ASINEX's oncology-oriented phenotypic library includes compounds based on several scaffolds with proven cytotoxicity (sub-µM EC50 in MTT assay) against a number of cancer cell lines: MV-411 (acute monocytic leukemia), HCT-116 (human colon cancer), MCF-7 (human breast adenocarcinoma‎), A-172 (Human glioblastoma), COLO-320 (colorectal adenocarcinoma), U-937 (histiocytic lymphoma), A-375 (malignant melanoma), BXPC-3 (pancreas adenocarcinoma), U118-MG (malignant glioma), and LN-229 (glioblastoma). Some active compounds were screened in a biochemical assay showing nM level of IC50 against several kinases: Aurora A, Haspin, VEGFR, EGFR, PDGFR.
SL#023
Oncology Phenotypic Screening-2
(Colon Cancer/Non-Macrocycle)
80 compounds / set
Pre-Plated Set
Update: 2016
ASINEX has evaluated the susceptibility of several colon cancer cell lines (HCT-116, SW-620, COLO-320, RKO) to a diverse array of small molecules and identified a series of related compounds that kill cancer cells at sub-µM concentrations with limited off target effect on healthy cells (human fibroblasts). Additional screening in a cell-based luciferase reporter assay of Wnt signaling has provided preliminary evidence of Wnt-dependent mechanism of action.
SL#035
Oncology Phenotypic Screening-3
(Macrocycles)
80 compounds / set
Pre-Plated Set
Update: 2016
ASINEX has evaluated the susceptibility of several cancer cell lines (i.e. RKO, HCT116, Molt-4, Rs4-11, U937, A549, H1568, H23, PANC1, A2780) to an array of peptidic and non-peptidic macrocycles and identified a series of compounds that kill cancer cells at µM concentrations.
Product Name: Format/Size Descriptions Download
Immuno-Oncology Library 6334 compounds
For cherry-picking
Update: 2020-07
The file contains all available Immuno-Oncology compounds selected from our Signature & BioDesign Libraries.
SL#021
IDO1 inhibitors
80 compounds
Pre-Plated Set
Release: 2016
By utilizing a combination of scaffold hopping and structure-based design strategies ASINEX has developed a library of small molecules for IDO1 drug discovery. Selected compounds have shown significant IDO1 inhibitory activity in vitro as measured in the enzymatic biochemical assays.
SL#026
IRAK4 inhibitors
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has created a series of IRAK4-oriented compounds by combining the IRAK4 hinge binding motif with proprietary natural product-like fragments. Several compounds from this library were screened against IRAK4 kinase in vitro and showed sub-uM IC50. Sunitinib was also included in the library as a reference compound.
SL#033
PD1/PD-L1 inhibitors
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has designed a set of novel small molecule probes that can be used for exploration of PD-1/PD-L1 signaling pathway.

You may also like:

Phenotypic Screening Sets: Format/Size Descriptions Download
Phenotypic Pre-Plated Set 13159 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2020-07
ASINEX has created a diverse set of molecules by applying strict physico-chemical and structural descriptors to ensure good solubility and permeability properties.
Asinex in GOSTAR 1878 compounds
41742 analogues
For cherry-picking
Update: 2020-11
Asinex have opted to use the Global Online Structure Activity Relationship Database (GOSTAR) as an integrated source of data capturing chemical, biological, pharmacological, and therapeutic parameters. The structural overlap between the Asinex (500K+) and GOSTAR (8M+) databases has revealed 17910 unique molecules with associated biological activity. Application of additional structural filters (PAINS, Eli Lilly [4-5]) has resulted in a set of 11923 compounds; diversity-oriented selection supported by computational and medicinal chemistry expertise has further refined this set resulting in 1878 molecules available for computational or in vitro evaluation. Biological diversity is represented by multiple target families where each molecule is associated with a GOSTAR record via a unique structure code identifier.
SL#004
Oncology Phenotypic Screening-1
(Non-Macrocycle)
80 compounds / set
Pre-Plated Set
Update: 2016
ASINEX's oncology-oriented phenotypic library includes compounds based on several scaffolds with proven cytotoxicity (sub-µM EC50 in MTT assay) against a number of cancer cell lines: MV-411 (acute monocytic leukemia), HCT-116 (human colon cancer), MCF-7 (human breast adenocarcinoma‎), A-172 (Human glioblastoma), COLO-320 (colorectal adenocarcinoma), U-937 (histiocytic lymphoma), A-375 (malignant melanoma), BXPC-3 (pancreas adenocarcinoma), U118-MG (malignant glioma), and LN-229 (glioblastoma). Some active compounds were screened in a biochemical assay showing nM level of IC50 against several kinases: Aurora A, Haspin, VEGFR, EGFR, PDGFR.
SL#023
Oncology Phenotypic Screening-2
(Colon Cancer/Non-Macrocycle)
80 compounds / set
Pre-Plated Set
Update: 2016
ASINEX has evaluated the susceptibility of several colon cancer cell lines (HCT-116, SW-620, COLO-320, RKO) to a diverse array of small molecules and identified a series of related compounds that kill cancer cells at sub-µM concentrations with limited off target effect on healthy cells (human fibroblasts). Additional screening in a cell-based luciferase reporter assay of Wnt signaling has provided preliminary evidence of Wnt-dependent mechanism of action.
SL#035
Oncology Phenotypic Screening-3
(Macrocycles)
80 compounds / set
Pre-Plated Set
Update: 2016
ASINEX has evaluated the susceptibility of several cancer cell lines (i.e. RKO, HCT116, Molt-4, Rs4-11, U937, A549, H1568, H23, PANC1, A2780) to an array of peptidic and non-peptidic macrocycles and identified a series of compounds that kill cancer cells at µM concentrations.
Product Name: Format/Size Descriptions Download
Targeted Oncology Library 4815 compounds
For cherry-picking
Update: 2020-07
The file contains all available Targeted-Oncology compounds selected from our Signature & BioDesign Libraries.
SL#029
IDH inhibitors - Cancer Metabolism
80 compounds
Pre-Plated Set
Release: 2016
Identified pharmacophore features of known IDH inhibitors and a subsequent search across the ASINEX corporate collection has revealed several quinolone-based analogs available at ASINEX. With these compounds as a starting point, ASINEX has applied its medicinal chemistry expertise in creating an array of novel small molecules potentially interesting for IDH-related research.
SL#043
State1(T) inhibitors of activated Ras
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has identified several rigid analogs of BPA that are able to coordinate with Metal(II) ions and can therefore be exploited as chemical probes for Ras-related research.
SL#053
Katanin inhibitors
80 compounds
Pre-Plated Set
Release: 2016
2D similarity search through ASINEX’s compound collection identified several close analogs of known katanin inhibitors that could be interesting for katanin-related research and MTA drug discovery.
SL#066
Inhibitors of miсroRNA-21
80 compounds
Pre-Plated Set
Release: 2017
Small molecules that can bind directly to microRNA-21 (miR-21) have been suggested as a promising new therapy for the treatment of cancer. Screening a large library of drug-like small molecules has identified several chemotypes that bind to the pre-miR-21 hairpin with high selectivity against other oligonucleotides. The most potent hit molecules share the common 1-amino-3-(9H-carbazol-9-yl)propan-2-ol scaffold which can be considered a privileged fragment. 80 molecules containing this privileged fragment were included in this library.
SL#071
Taxol pharmacophore chemical probes
80 compounds
Pre-Plated Set
Release: 2017
80 close analogs of the reported hits have been included in this library.
SL#085
Tubulin Inhibitors
80 compounds
Pre-Plated Set
Release: 2018
A series of novel phenoxazine and phenothiazine derivatives have been recently reported as privileged chemotypes in the discovery and development of novel tubulin polymerization inhibitors. Computational studies suggested that these compounds bind to β-tubulin at the colchicine binding site. Structural analogs of the reported hit series were included into this library.
SL#087
elF4A3 inhibitors
80 compounds
Pre-Plated Set
Release: 2018
A series of 5-(piperazine-1-carbonyl)pyridin-2(1H)-one derivatives have been identified as useful probe molecules for studying the eIF4A3 cell biology and exploring its therapeutic potential in cancer models. A similarity search through ASINEX’s compound collection identified several analogs of the reported inhibitors.

You may also like:

Product Name: Format/Size Descriptions Download
SL#003
Wnt/β-catenin Pathway Inhibitors
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has screened 21000 small molecules in a luciferase reporter assay using the colorectal cancer cell lines, SW620 (APC mutation) and HCT116 (GSK3b mutation). Selected primary hits were optimized to yield an array of active compounds showing EC50 0.1-5 uM. The most promising compounds down regulate the expression of the key WNT oncogenes: DKK, cycD, CD44.
SL#001
Mcl-1 Apoptosis
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has developed several acylsulfonamide derivatives with Mcl-1 binding potency and improved physico-chemical characteristics.
SL#002
Bcl-xL Apoptosis
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has identified dihydrobenzofurane as a functional a-helix mimetic displaying uM Bcl-xL binding affinity determined by a fluorescence polarization assay.
SL#011
MDM2-p53 (α-Helix mimetics)
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has performed in-silico analyses of common structural futures of known MDM2 antagonists to build up a predictive pharmacophore model [1]. Several ɑ-helix mimetic scaffolds were selected as p53 backbone mimetics and p53 binding epitope mimetics [2,3]. The in vitro potency of compounds was confirmed in a fluorescence polarization assay, with the IC50s ranging from 1 to 10 µM.
Product Name: Format/Size Descriptions Download
Immuno-Oncology Library 6334 compounds
For cherry-picking
Update: 2020-07
The file contains all available Immuno-Oncology compounds selected from our Signature & BioDesign Libraries.
SL#021
IDO1 inhibitors
80 compounds
Pre-Plated Set
Release: 2016
By utilizing a combination of scaffold hopping and structure-based design strategies ASINEX has developed a library of small molecules for IDO1 drug discovery. Selected compounds have shown significant IDO1 inhibitory activity in vitro as measured in the enzymatic biochemical assays.
SL#026
IRAK4 inhibitors
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has created a series of IRAK4-oriented compounds by combining the IRAK4 hinge binding motif with proprietary natural product-like fragments. Several compounds from this library were screened against IRAK4 kinase in vitro and showed sub-uM IC50. Sunitinib was also included in the library as a reference compound.
SL#033
PD1/PD-L1 inhibitors
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has designed a set of novel small molecule probes that can be used for exploration of PD-1/PD-L1 signaling pathway.
Phenotypic Screening Sets: Format/Size Descriptions Download
Phenotypic Pre-Plated Set 13159 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2020-07
ASINEX has created a diverse set of molecules by applying strict physico-chemical and structural descriptors to ensure good solubility and permeability properties.
Asinex in GOSTAR 1878 compounds
41742 analogues
For cherry-picking
Update: 2020-11
Asinex have opted to use the Global Online Structure Activity Relationship Database (GOSTAR) as an integrated source of data capturing chemical, biological, pharmacological, and therapeutic parameters. The structural overlap between the Asinex (500K+) and GOSTAR (8M+) databases has revealed 17910 unique molecules with associated biological activity. Application of additional structural filters (PAINS, Eli Lilly [4-5]) has resulted in a set of 11923 compounds; diversity-oriented selection supported by computational and medicinal chemistry expertise has further refined this set resulting in 1878 molecules available for computational or in vitro evaluation. Biological diversity is represented by multiple target families where each molecule is associated with a GOSTAR record via a unique structure code identifier.
SL#004
Oncology Phenotypic Screening-1
(Non-Macrocycle)
80 compounds / set
Pre-Plated Set
Update: 2016
ASINEX's oncology-oriented phenotypic library includes compounds based on several scaffolds with proven cytotoxicity (sub-µM EC50 in MTT assay) against a number of cancer cell lines: MV-411 (acute monocytic leukemia), HCT-116 (human colon cancer), MCF-7 (human breast adenocarcinoma‎), A-172 (Human glioblastoma), COLO-320 (colorectal adenocarcinoma), U-937 (histiocytic lymphoma), A-375 (malignant melanoma), BXPC-3 (pancreas adenocarcinoma), U118-MG (malignant glioma), and LN-229 (glioblastoma). Some active compounds were screened in a biochemical assay showing nM level of IC50 against several kinases: Aurora A, Haspin, VEGFR, EGFR, PDGFR.
SL#023
Oncology Phenotypic Screening-2
(Colon Cancer/Non-Macrocycle)
80 compounds / set
Pre-Plated Set
Update: 2016
ASINEX has evaluated the susceptibility of several colon cancer cell lines (HCT-116, SW-620, COLO-320, RKO) to a diverse array of small molecules and identified a series of related compounds that kill cancer cells at sub-µM concentrations with limited off target effect on healthy cells (human fibroblasts). Additional screening in a cell-based luciferase reporter assay of Wnt signaling has provided preliminary evidence of Wnt-dependent mechanism of action.
SL#035
Oncology Phenotypic Screening-3
(Macrocycles)
80 compounds / set
Pre-Plated Set
Update: 2016
ASINEX has evaluated the susceptibility of several cancer cell lines (i.e. RKO, HCT116, Molt-4, Rs4-11, U937, A549, H1568, H23, PANC1, A2780) to an array of peptidic and non-peptidic macrocycles and identified a series of compounds that kill cancer cells at µM concentrations.
Contact
Global

Ludmila Sadovenko

lsadovenko@asinex.com
North America

Mark Parisi

mparisi@asinex.com

Toll Free: +1 877 ASINEX1

Tel: +1 336 721 1617

Fax: +1 336 721 1618

N.Chestnut St., Ste.104

Winston-Salem, NC 27101

USA

Europe

Galina Afanasyeva

gafanasyeva@asinex.com

Tel: +31 (0) 203416183

Klaprozenweg 75C, 1033NN

Amsterdam, The Netherlands

Japan

Shingo Ota

sota@asinex.com

Tel: 080-3401-9097

30-2 Higashihazu, Nishio,

Aichi Japan

Cart
Your cart is empty
Order
$
0
Checkout
Thanks for your order
We will contact you shortly